|
Vitruvia Medical AG / Key word(s): Annual Results/Annual Report Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023 25-Jun-2023 / 09:59 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023 Anglikon, June 25, 2023: Vitruvia Medical AG reported net income after taxes of CHF -1,095,349.38 for the year ended December 31, 2022, compared to CHF -8,002,497.53 in the previous year. On a consolidated basis, Vitruvia Medical AG generated revenues of EUR 1,525,529.– and operating earnings before interest, taxes, depreciation and amortization (EBITA) of EUR -912,086. Earnings after taxes amount to EUR -1,484,556 compared to the previous year of EUR -8,131,520.00. Outlook 2023 For the current year, Vitruvia Medical AG and its subsidiary LT technologies GmbH & Co. KG to generate revenues of approximately EUR 1.8 million and earnings (before interest, taxes, depreciation and amortization) of approximately EUR 304,000 (unconsolidated). On a consolidated basis, Vitruvia Medical AG expects a further improvement in earnings compared to the previous year, which will, however, still be in negative territory. About Vitruvia Medical AG: Vitruvia Medical AG is a Swiss investment company focused on the repair, production and trade of medical devices as well as surgical instruments. Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success. Vitruvia Medical AG Markus A. Bertschin President of the Board of Directors Kesselackerstrasse 18 CH-5611 Anglikon End of Inside Information 25-Jun-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Dreams of cancer vaccines are becoming more real. Here are 9 scientists making it happen
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other
October 29, 2024